Eton Pharmaceuticals (ETON) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 159.5% versus a gain of 4.7%. Over five years, ETON leads with a +953.4% price change compared with +37.2% for NBIX. Neurocrine Biosciences is the larger company by market cap ($14.45 billion vs $1.56 billion), about 9.2 times the size.
On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.0x vs 21.2x for Eton Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | NBIX |
|---|---|---|
| Share price | $54.72 | $142.17 |
| Market cap | $1.56B | $14.45B |
| 1-day change | -0.30% | -0.91% |
| YTD return | +224.54% | +1.16% |
| 1-year return | +159.48% | +4.72% |
| 5-year return | +953.36% | +37.24% |
| P/E ratio (TTM) | 136.79 | 20.85 |
| Forward P/E | 21.21 | 11.97 |
| EPS (TTM) | $0.40 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $478.60M |
| Gross margin | — | 98.18% |
| Operating margin | — | 21.64% |
| Net margin | — | 16.73% |
| 52-week high | $66.37 | $186.12 |
| 52-week low | $14.27 | $122.14 |
| Distance from 52-week high | -17.56% | -23.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.76% | +45.80% |
| Average volume | 606.07K | 1.30M |
| Shares outstanding | 28.58M | 101.65M |
| Employees | 44 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neurocrine Biosciences is about 9.2 times larger than Eton Pharmaceuticals by market value ($14.45B vs $1.56B).
- ETON has outperformed NBIX by 154.8 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (136.8x vs 20.8x trailing P/E).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
ETON vs NBIX FAQ
Which is bigger, Eton Pharmaceuticals or Neurocrine Biosciences?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.45B compared with $1.56B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or NBIX?
ETON returned +159.48% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ETON or NBIX?
NBIX has the lower trailing P/E at 20.8, versus 136.8 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Eton Pharmaceuticals and Neurocrine Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Eton Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Neurocrine Biosciences.